



Highest Recruiter in April



A massive congratulations to Dr Luis Máiz Carro from Ramón y Cajal Hospital in Madrid for being this month's highest recruiter!

Follow us on Twitter @EMBARCnetwork



Connect with us on LinkedIn



Please remember to visit the EMBARC homepage for links to all the latest publications and news in regards to our Network members. If you have a recent paper we have not displayed and would like it to be highlighted on the homepage please let us know.

If there is anything in particular you wish to see in the newsletter or online, please do let us know, info@bronchiectasis.eu

2ND WORLD BRONCHIECTASIS CONFERENCE

MILAN 6 - 8 JULY 2017



CONGRATULATIONS!!

Two lucky winners have been chosen! Congratulations to Dr Lotte Terpstra from the Netherlands and Onie Hove from the UK who have successfully secured their free places at this year's World Bronchiectasis Conference in Milan. We look forward to meeting with you!

The preliminary programme for this three day event is now available to view online or to download [here](#)

As a gentle reminder, the deadline for abstract submission is 8th May with the best abstracts being published in Multidisciplinary Respiratory Medicine in a special issue on Bronchiectasis!



The European Bronchiectasis Registry



Details of how to submit an abstract, registration fees or for more information in relation to the conference please [visit](#)

EMBARC-NTM Registry

EMBARC is delighted to announce that the first patient has been enrolled in the EMBARC-NTM study. Congratulations to Dr Stefano Aliberti in Italy for recruiting the first patient.

The new European Registry for non-tuberculous Mycobacteria (NTM) infections is supported by the existing infrastructure of EMBARC and covers an area of acute need with limited clinical data available in Europe.

New centres will be opening soon/getting the invitation to participate. If you would like to join the project please contact the study coordinator for more information.



ERS EUROPEAN RESPIRATORY SOCIETY

every breath counts

The new ERS bronchiectasis guidelines will be presented in September at this year's annual congress in Milan.

ERS are accepting late-breaking abstracts for the International Congress between 1 – 31 May, 2017. Don't miss the opportunity to present your work at the largest respiratory event of the year.

For further information about attending ERS 2017 please visit www.erscongress.org

IMPORTANT

When completing the microbiology eCRF page, if no organism was detected in the sample, the "Add" button must still be selected to "lock" in the selection.

The MRC score MUST be collected from the patient in order for the CRF page to complete for submission.

When completing Annual Reviews, all pages of the eCRF still need to be completed to show any changes since the previous data capture. This also applies to those who are having their final data capture due to withdraw / discharge or those who have died. Please follow the instructions directed by the eCRF.

New Publications from the EMBARC Network

- ◇ *Pseudomonas aeruginosa* adaptation and diversification in the non-cystic fibrosis bronchiectasis lung
Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, Walshaw MJ, Williams D, Fothergill JL, De Soyza A, Winstanley C.
European Respiratory Journal 2017 49: 1602108; DOI: 10.1183/13993003.02108-2016
<http://erj.ersjournals.com/content/49/4/1602108.long>
- ◇ *Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts.*
Athanazio R, Pereira MC, Gramblicka G, Cavalcanti-Lundgren F, de Figueiredo MF, Arancibia F, Rached S, de la Rosa D, Máiz-Carro L, Girón R, Oliveira C, Prados C, Martinez-Garcia MA.
BMC Pulm Med. 2017 Apr 6;12(4):73. DOI: 10.1186/s12890-017-0417-3.
<https://bmcpulmed.biomedcentral.com/articles/10.1186/s12890-017-0417-3>
- ◇ *Non-cystic fibrosis bronchiectasis: from pragmatic management to personalized medicine*
Munteanu O, Salzer HJF
PMID: 28445890 DOI:10.1159/000473885
<https://www.ncbi.nlm.nih.gov/pubmed/28445890>
- ◇ *Patterns of disease in patients with middle-lobe predominant bronchiectasis*
McDonnell MJ, Ahmed M, Das J, O'Mahony M, Breen D, O'Regan A, Gilmartin JJ, Bruzzi J, Rutherford RM.
Respiration. 2017 Apr 20. doi: 10.1159/000464252. [Epub ahead of print]
<https://www.ncbi.nlm.nih.gov/pubmed/28423372>
- ◇ *Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis.*
Emilie Vallières, Karen Tumelty, Michael M. Tunney, Rosemary Hannah, Oonagh Hewitt, J. Stuart Elborn, Damian G. Downey
European Respiratory Journal 2017 49: 1600851; DOI: 10.1183/13993003.00851-2016
<http://erj.ersjournals.com/content/49/4/1600851.long>
- ◇ *Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations.*
Rosales-Mayor E, Polverino E, Raguer L, Alcaraz V, Gabarrus A, Ranzani O, Menendez R, Torres A.
PLoS One. 2017 Apr 6;12(4):e0175171. DOI: 10.1371/journal.pone.0175171. eCollection 2017.
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175171>
- ◇ *The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies*
Wells TJ, Davison J, Sheehan E, Kanagasundaram S, Spickett G, MacLennan CA, Stockley RA, Cunningham AF, Henderson IR, De Soyza A.
Am J Respir Crit Care Med. 2017 Apr 1;195(7):955-958. DOI: 10.1164/rccm.201603-0599LE. No abstract available.
http://www.atsjournals.org/doi/abs/10.1164/rccm.201603-0599LE?url_ver=Z39.88-2003&rft_id=ori:rid:crossref.org&rft_dat=cr_pub%3dpubmed
- ◇ *New Therapies for the prevention and treatment of exacerbations in bronchiectasis*
Abo-Leyah H, Chalmers JD
Curr Opin Pulm Med. 2017 May;23(3):218-224. DOI: 10.1097/MCP.0000000000000368.
<https://www.ncbi.nlm.nih.gov/pubmed/28212153>

***** IMPORTANT *****

There are still a number of invoices being sent to the wrong address and/or with incorrect details. We cannot stress how important it is to follow the below instructions.

- Payment can only be made for cases which have been quality checked and **Approved** for the registry. You can see which cases have been Approved under the 'status' column on the eCRF.
- Invoices must be written in English and clearly state a breakdown of how many Baseline cases and how many Review cases are being invoiced for as these are costed differently.
- The billing address must contain **University of Dundee**
- Invoices can only be paid to institution accounts and not personal accounts. It is at the discretion of the centre to how this recruitment payment is spent eg staff payments, however the money must first pass through your hospital/University/Department.
- **Please ensure those who raise invoices for your centre are aware of the above information.**
- Delays in payment should be expected when instructions are not followed.

It is the responsibility of each Centre to raise invoices for their recruitment.

The central team will not send reminders.

All invoices must be in English and addressed to;

The European Bronchiectasis Registry
Clinical Research Centre
James Arrott Drive
University of Dundee
Ninewells Hospital and Medical School
Dundee DD1 9SY, UK

Alternatively, they can be emailed directly to the study coordinator;

m.l.crichton@dundee.ac.uk